President Donald Trump named Robert Wilkie, a veteran GOP aide and acting secretary of the Veterans Affairs (VA), to lead the VA; with the power of a pen, HHS Secretary Alex Azar is eager to play the role of a “joyful regulator;” patients with amyotrophic lateral sclerosis (ALS) are finding they are caught between hope, expectations, and insurers that won’t pay for a $145,000 intravenous drug.
President Donald Trump named Robert Wilkie, a veteran GOP aide and acting secretary of the Department of Veterans Affairs (VA), to become the permanent leader of the VA. Wilkie has led the troubled agency as acting chief since March. Ronny Jackson, MD, the president’s former personal physician, withdrew from consideration to lead the VA last month amid scandal over his workplace behavior. As a former adviser to Senator Thom Tillis, R-North Carolina, Wilkie’s confirmation will likely be smoother than Jackson’s, Politico reported.
With the power of a pen, HHS Secretary Alex Azar is eager to play the role of a “joyful regulator,” The New York Times reported over the weekend, in a profile of the president’s front man running the administration’s drug pricing policy. Avalere’s president Dan Mendelson called him the total opposite of his HHS predecessor Tom Price, MD, who focused more on deregulation, whereas Azar looks to see which regulations he can write or rewrite, rather than just cancel.
Patients with amyotrophic lateral sclerosis (ALS), known as Lou Gehrig disease, are finding they are caught between hope, expectations, and insurers that won’t pay for a $145,000 intravenous drug, called Radicava, for their incurable disease, even though it was approved by the FDA last year for all patients. The issue is at what point in the progressive disease the drug will be most effective, a point not fully explored in a small clinical trial, STAT reported. The manufacturer, MT Pharma, says that research expense must be recouped.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More